Literature DB >> 33376103

Long-Term Safety of Tolvaptan in ADPKD: Where Do We Stand?

Dipal M Patel1, Neera K Dahl2.   

Abstract

Entities:  

Keywords:  ADPKD; Tolvaptan; autosomal dominant polycystic kidney disease; clinical trial; safety

Mesh：

Substances：

Year:  2020        PMID： 33376103      PMCID： PMC7792649          DOI： 10.2215/CJN.17981120

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  10 in total

1.  Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Ronald D Perrone; Ann Dandurand; John Ouyang; Frank S Czerwiec; Jaime D Blais
Journal:  Nephrol Dial Transplant       Date:  2017-07-01       Impact factor: 5.992

Review 2.  Autosomal dominant polycystic kidney disease.

Authors:  Emilie Cornec-Le Gall; Ahsan Alam; Ronald D Perrone
Journal:  Lancet       Date:  2019-02-25       Impact factor: 79.321

3.  Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan.

Authors:  Manuel A Anderegg; Nasser A Dhayat; Grit Sommer; Mariam Semmo; Uyen Huynh-Do; Bruno Vogt; Daniel G Fuster
Journal:  Kidney Med       Date:  2020-02-26

4.  A Post Hoc Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials.

Authors:  Susan E Shoaf; John Ouyang; Olga Sergeyeva; Alvin Estilo; Hui Li; Deborah Leung
Journal:  Clin J Am Soc Nephrol       Date:  2020-04-02       Impact factor: 8.237

5.  Tolvaptan in patients with autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Jared J Grantham; Eiji Higashihara; Ronald D Perrone; Holly B Krasa; John Ouyang; Frank S Czerwiec
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

6.  Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Ronald D Perrone; Gary Koch; John Ouyang; Robert D McQuade; Jaime D Blais; Frank S Czerwiec; Olga Sergeyeva
Journal:  N Engl J Med       Date:  2017-11-04       Impact factor: 91.245

Review 7.  A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.

Authors:  Fouad T Chebib; Ronald D Perrone; Arlene B Chapman; Neera K Dahl; Peter C Harris; Michal Mrug; Reem A Mustafa; Anjay Rastogi; Terry Watnick; Alan S L Yu; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2018-09-18       Impact factor: 10.121

8.  Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Ronald D Perrone; Jennifer Lee; Molly E Hoke; Alvin Estilo; Olga Sergeyeva
Journal:  Clin J Am Soc Nephrol       Date:  2020-12-29       Impact factor: 8.237

9.  Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database.

Authors:  Paul B Watkins; James H Lewis; Neil Kaplowitz; David H Alpers; Jaime D Blais; Dan M Smotzer; Holly Krasa; John Ouyang; Vicente E Torres; Frank S Czerwiec; Christopher A Zimmer
Journal:  Drug Saf       Date:  2015-11       Impact factor: 5.606

10.  Role of Liver Transplantation in Tolvaptan-Associated Acute Liver Failure.

Authors:  Mayumi Endo; Kan Katayama; Hiroshi Matsuo; Shinichiro Horiike; Shinsuke Nomura; Akinobu Hayashi; Eiji Ishikawa; Tetsuro Harada; Ryosuke Sugimoto; Akihiro Tanemura; Kazushi Sugimoto; Shuji Isaji; Masaaki Ito
Journal:  Kidney Int Rep       Date:  2019-09-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.